Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics July 13, 2021
Sitryx Licenses Intellectual Property Rights for Inhibitors of a New Target in Immunometabolism from Cancer Research UK in Exclusive Worldwide Agreement July 12, 2021
Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set June 25, 2021
